APGE Quote, Financials, Valuation and Earnings

Dyne Therapeutics, Inc. has a net margin of -- compared to Apogee Therapeutics, Inc.'s net margin of --. Apogee Therapeutics, Inc.'s return on equity of -38.09% beat Dyne Therapeutics, Inc.'s return on equity of -64.85%.

Apogee Therapeutics, Inc. has a consensus price target of $104.29, signalling upside risk potential of 50.46%. On the other hand Dyne Therapeutics, Inc. has an analysts' consensus of $39.13 which suggests that it could grow by 144.53%. Given that Dyne Therapeutics, Inc. has higher upside potential than Apogee Therapeutics, Inc., analysts believe Dyne Therapeutics, Inc. is more attractive than Apogee Therapeutics, Inc..

Apogee Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dyne Therapeutics, Inc. has a beta of 1.302, suggesting its more volatile than the S&P 500 by 30.201%.

Apogee Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dyne Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apogee Therapeutics, Inc. pays -- of its earnings as a dividend. Dyne Therapeutics, Inc. pays out -- of its earnings as a dividend.

Apogee Therapeutics, Inc. quarterly revenues are --, which are smaller than Dyne Therapeutics, Inc. quarterly revenues of --. Apogee Therapeutics, Inc.'s net income of -$65M is higher than Dyne Therapeutics, Inc.'s net income of -$108M. Notably, Apogee Therapeutics, Inc.'s price-to-earnings ratio is -- while Dyne Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apogee Therapeutics, Inc. is -- versus -- for Dyne Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Galecto, Inc. has a net margin of -- compared to Apogee Therapeutics, Inc.'s net margin of --. Apogee Therapeutics, Inc.'s return on equity of -38.09% beat Galecto, Inc.'s return on equity of -123.72%.

Apogee Therapeutics, Inc. has a consensus price target of $104.29, signalling upside risk potential of 50.46%. On the other hand Galecto, Inc. has an analysts' consensus of $44.33 which suggests that it could grow by 47.63%. Given that Apogee Therapeutics, Inc. has higher upside potential than Galecto, Inc., analysts believe Apogee Therapeutics, Inc. is more attractive than Galecto, Inc..

Apogee Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Galecto, Inc. has a beta of 1.422, suggesting its more volatile than the S&P 500 by 42.247%.

Apogee Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galecto, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apogee Therapeutics, Inc. pays -- of its earnings as a dividend. Galecto, Inc. pays out -- of its earnings as a dividend.

Apogee Therapeutics, Inc. quarterly revenues are --, which are smaller than Galecto, Inc. quarterly revenues of --. Apogee Therapeutics, Inc.'s net income of -$65M is lower than Galecto, Inc.'s net income of -$3.1M. Notably, Apogee Therapeutics, Inc.'s price-to-earnings ratio is -- while Galecto, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apogee Therapeutics, Inc. is -- versus -- for Galecto, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Structure Therapeutics, Inc. has a net margin of -- compared to Apogee Therapeutics, Inc.'s net margin of --. Apogee Therapeutics, Inc.'s return on equity of -38.09% beat Structure Therapeutics, Inc.'s return on equity of -25.55%.

Apogee Therapeutics, Inc. has a consensus price target of $104.29, signalling upside risk potential of 50.46%. On the other hand Structure Therapeutics, Inc. has an analysts' consensus of $107.80 which suggests that it could grow by 49.64%. Given that Apogee Therapeutics, Inc. has higher upside potential than Structure Therapeutics, Inc., analysts believe Apogee Therapeutics, Inc. is more attractive than Structure Therapeutics, Inc..

Apogee Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Structure Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Apogee Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Structure Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apogee Therapeutics, Inc. pays -- of its earnings as a dividend. Structure Therapeutics, Inc. pays out -- of its earnings as a dividend.

Apogee Therapeutics, Inc. quarterly revenues are --, which are smaller than Structure Therapeutics, Inc. quarterly revenues of --. Apogee Therapeutics, Inc.'s net income of -$65M is higher than Structure Therapeutics, Inc.'s net income of -$65.8M. Notably, Apogee Therapeutics, Inc.'s price-to-earnings ratio is -- while Structure Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apogee Therapeutics, Inc. is -- versus -- for Structure Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Apogee Therapeutics, Inc.'s net margin of 21.74%. Apogee Therapeutics, Inc.'s return on equity of -38.09% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Apogee Therapeutics, Inc. has a consensus price target of $104.29, signalling upside risk potential of 50.46%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $867.85 which suggests that it could grow by 10.74%. Given that Apogee Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Apogee Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Apogee Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Apogee Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Apogee Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Apogee Therapeutics, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Apogee Therapeutics, Inc.'s net income of -$65M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Apogee Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apogee Therapeutics, Inc. is -- versus 5.93x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.